Journal
EUROPEAN JOURNAL OF ENDOCRINOLOGY
Volume 154, Issue 6, Pages 805-806Publisher
BIO SCIENTIFICA LTD
DOI: 10.1530/eje.1.02160
Keywords
-
Categories
Ask authors/readers for more resources
We report on a patient with acromegaly who developed severe drug-induced hepatitis during combined treatment with the long-acting somatostatin-analog octreotide and the GH receptor antagonist pegvisomant. The hepatic enzyme disturbances normalized after discontinuation of pegvisomant. After rechallenge with monotherapy pegvisomant. however, the hepatic enzyme disturbances reappeared within a few weeks. indicating that most likely pegvisomant alone and not the long-acting somatostatin analog or the combination of these two drugs was responsible for this case of drug-induced hepatitis. Clinicians Should be aware of this potential severe adverse drug reaction and therefore frequent control of hepatic enzymes is mandatory during treatment with pegvisomant.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available